中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 7
Jul.  2016
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2016  >  32(7): 1364-1367

Value of serum carbohydrate antigens 19-9 and 24-2 in diagnosis of benign and malignant biliary tract diseases

DOI: 10.3969/j.issn.1001-5256.2016.07.033
Research funding:

 

  • Published Date: 2016-07-20
    Abstract
  • Objective To investigate the value of serum carbohydrate antigen 19- 9( CA19- 9) and carbohydrate antigen 24- 2( CA24-2) in the diagnosis of benign and malignant biliary tract diseases. Methods A total of 214 patients with biliary tract diseases who were hospitalized in Department of Gastroenterology and Department of General Surgery in the First Hospital Affiliated to Hebei North University from January 2012 to October 2015 were enrolled,and according to the nature of lesions,they were divided into benign lesion group( 162 patients) and malignant lesion group( 52 patients). The healthy people who underwent physical examination during the same period of time in the Physical Examination Center were enrolled as normal control group( 40 persons). Peripheral venous blood was collected for all subjects in a fasting state,and the serum levels of total bilirubin( TBil),direct bilirubin( DBil),and indirect bilirubin( IBil) were measured. Radioimmunoassay was used to measure the serum levels of CA19- 9 and CA24- 2. The Kruskal- Wallis H test was used for comparison of continuous data between multiple groups,and the Wilcoxon rank sum test was used for further comparison between any two groups; the chi-square test was used for comparison of categorical data between groups; Pearson correlation analysis was also performed. Results Compared with the normal control group,the benign lesion group and the malignant lesion group showed significant increases in the serum levels of TBil and CA19- 9( all P < 0. 01). Compared with the benign lesion group,the malignant lesion group showed significant increases in the serum levels of CA19- 9 and CA24- 2( all P < 0. 01). The serum levels of CA19- 9 and CA24- 2 were not associated with tumor location in cholangiocarcinoma,but they were associated with the degree of tumor differentiation( χ2= 6. 860 and 9. 010,all P < 0. 05). The combined measurementof CA 1 9- 9 and CA 2 4- 2 had a sensitivity of 8 8. 5 % and a specificity of 8 2. 1 % in the diagnosis of cholangiocarcinoma,which were significantly higher than the sensitivity and specificity of CA19- 9 or CA24- 2 measurement( all P < 0. 01). In the patients with benign biliary tract diseases and cholangiocarcinoma,serum CA19- 9 was positively correlated with serum TBil( r = 0. 634 and 0. 346,both P < 0. 05),and the benign lesion group had a significantly greater correlation between serum CA19- 9 and serum TBil than the malignant lesion group. Conclusion Combined measurement of CA19- 9 and CA24- 2 has clinical significance in early diagnosis of cholangiocarcinoma.

     

    • FullText(HTML)
    • References(15)
  • [1]XIONG HL,FAN Y,HU M,et al.The clinical value of serum CA199 in benign and malign biliary tract disease[J].Chin J Clin Gastroenterol,2013,25(6):327-329.(in Chinese)熊会玲,范彦,胡美,等.血清CA199对良恶性胆道疾病的意义[J].临床消化病杂志,2013,25(6):327-329.
    [2]LIU SL,XING GZ,ZHANG YH,et al.The valuable tumormarkers of CEA and CA19-9 in the bile for diagnosis of cholangiocarcinoma and carcinoma of ampulla[J].J Clin Hepatol,2009,25(2):125-126.(in Chinese)刘素丽,邢国璋,张月寒,等.胆汁CEA、CA19-9联合检测对肝外胆管癌及壶腹癌的诊断价值[J].临床肝胆病杂志,2009,25(2):125-126.
    [3]JIN ZD,LI ZS.Digestive Ultrasonic Endoscopy[M].Beijing:Science Press,2006:421-548.(in Chinese)金震东,李兆申.消化超声内镜学[M].北京:科学出版社,2006:421-548.
    [4]CHEN WW,ZHOU SS,YAN S.Value of combined measurement of serum CA19-9 and CA242 in diagnosis of cholangiocarcinoma[J].Zhejiang Clin Med J,2014,16(3):368-369.(in Chinese)陈微微,周思思,严苏.血清CA19-9 CA242联合检测诊断胆管癌的价值[J].浙江临床医学,2014,16(3):368-369.
    [5]CHUNG YJ,CHOI DW,CHOI SH,et al.Prognostic factors following surgical resection of distal bile duct cancer[J].J Korean Surg Soc,2013,85(5):212-218.
    [6]DONG CG,WANG SM,SU WB.Research progress on combined measurement of tumor markers in the diagnosis of hilar cholangiocarcinoma[J].China Modern Med,2015,5(22):17-19.(in Chinese)董晨光,王世明,苏文博.肿瘤标志物联合检测在肝门胆管癌诊断中的研究进展[J].中国当代医药,2015,5(22):17-19.
    [7]ZHU YB,GE SH,ZHANG LH,et al.Clinical value of serum CEA,CA19-9,CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer[J].Chin J Gastrointestinal Surg,2012,15(2):161-164.(in Chinese)朱昱冰,葛少华,张连海,等.肿瘤标志物在胃癌患者中的诊断及预后价值[J].中华胃肠外科杂志,2012,15(2):161-164.
    [8]CHEN LB,HUANG DB.Diagnostic value of joint determination of serum CA199,CysC and Hcy levels in patients with pancreatic cancer[J].Chin J Health Lab Tec,2014,24(9):1265-1266.(in Chinese)陈乐宝,黄东标.CA199、CysC和Hcy联检对胰腺癌的诊断价值[J].中国卫生检验杂志,2014,24(9):1265-1266.
    [9]LI J,LIANG XF,ZHAI GL.Application of combined detection of serum levels of CA199,CA125 and CEA in diagnosis of pancreatic cancer[J].J Jilin Univ:Med Edit,2014,40(6):1252-1255.(in Chinese)李静,梁晓芳,翟桂兰.血清CA199、CA125和CEA联合检测在胰腺癌诊断中的应用[J].吉林大学学报:医学版,2014,40(6):1252-1255.
    [10]HOU JJ,HU SY,LIU TT,et al.Clinical value of serum tumor marker in early diagnosis ovarian cancer[J].Chin J Immunol,2014,30(8):1101-1107.(in Chinese)侯娟娟,虎淑妍,刘婷婷,等.血清肿瘤标志物在卵巢癌早期诊断中的临床价值[J].中国免疫学杂志,2014,30(8):1101-1107.
    [11]FENG J,SHEN Q,PAN QC.The clinical significance of serum tumor markers in patients with choledocholithiasis[J].Chin J Gastroenterol Hepatol,2016,25(2):212-214.(in Chinese)冯洁,沈强,潘勤聪.胆总管结石患者血清肿瘤标志物的临床意义[J].胃肠病学和肝病学杂志,2016,25(2):212-214.
    [12]SONG HW,JIANG YG,ZHANG SJ,et al.Relationship of serum CA199 levels with cholangiolithiasis and cholangitis[J].Chin JGastroenterol Hepatol,2013,22(12):1267-1268.(in Chinese)宋惠雯,蒋义贵,张生君,等.血清CA199与胆管结石及胆管炎的关系[J].胃肠病学和肝病学杂志,2013,22(12):1267-1268.
    [13]TZENG CW,BALACHANDRAN A,AHMAD M,et al.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer[J].HPB(Oxford),2014,16(5):430-438.
    [14]CHEN S,MU D,CUI M,et al.Dynamic changes and clinical significance of serum tryptase levels in STEMI patients treated with primary PCI[J].Biomarkers,2014,19(7):620-624.
    [15]LIN MS,HUANG JX,YU H.Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker[J].Int J Clin Exp Med,2014,7(3):744-750.
    • Relative Articles

  • Relative Articles

    [1]Huaqiang ZHANG, Lixin LIU, Xiaohong GUO. Association of nonalcoholic fatty liver disease with the risk of colorectal adenoma and colorectal cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(7): 1619-1625. doi: 10.3969/j.issn.1001-5256.2021.07.028
    [2]Qiaohong LIU, Yu ZHAO, Yiyang HU. Effect of diet on enterotype-related gut microbiota in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 939-942. doi: 10.3969/j.issn.1001-5256.2021.04.046
    [3]Juan PENG, Liangping LI. Mechanism of action of estrogen and its receptor in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 467-470. doi: 10.3969/j.issn.1001-5256.2021.02.046
    [4]Jinhong TANG, Long WANG. Research advances in the association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2021, 37(11): 2672-2675. doi: 10.3969/j.issn.1001-5256.2021.11.040
    [5]Yalan LEI, Jian BI, Jingwei MAO. Impact of nonalcoholic fatty liver disease on intestinal immune cells[J]. Journal of Clinical Hepatology, 2021, 37(11): 2667-2671. doi: 10.3969/j.issn.1001-5256.2021.11.039
    [6]Shenglan ZENG, Rongzhen ZHANG, Na WANG, Tingshuai WANG, Liting TAN, Dewen MAO. Effect of diet-gut microbiota axis on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2676-2679. doi: 10.3969/j.issn.1001-5256.2021.11.041
    [7]Chenlu ZHAO, Wenxia ZHAO. Influence of estrogen deficiency on metabolic associated fatty liver disease in postmenopausal women[J]. Journal of Clinical Hepatology, 2021, 37(7): 1708-1712. doi: 10.3969/j.issn.1001-5256.2021.07.049
    [8]Tian TIAN, Wenwei HU, Xue LI, Jie WU, Dan ZHANG, Changzheng LI. Association between thyroxine level and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2357-2363. doi: 10.3969/j.issn.1001-5256.2021.10.020
    [9]Xiangqian HUANG, Xiaomeng YAN, Mingda ZHANG, Jing WU, Jianhong CHEN. Association between nonalcoholic fatty liver disease and colorectal neoplasms[J]. Journal of Clinical Hepatology, 2021, 37(12): 2947-2950. doi: 10.3969/j.issn.1001-5256.2021.12.045
    [10]SUN MengYuan, XIANG XiaoXing. Role of gut microbiota and bile acid pathway in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(12): 2831-2834. doi: 10.3969/j.issn.1001-5256.2020.12.040
    [11]Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
    [12]Hui DengCheng, Sun MingYu. Association between nonalcoholic fatty liver disease and gut microbiota based on the theory of gut-liver axis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1627-1630. doi: 10.3969/j.issn.1001-5256.2020.07.039
    [13]Zhang Dan, Zhou Bo, Deng Yi, Wen Yu, Lu: JunYan, Wang JinXiang, Geng ZuoTao, Luo SuFeng, Ying YunYan, Wen DaiYan, Shi ChunJing, Pu GuangYu, Jiang Xin, Ma LanQing. Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 829-834. doi: 10.3969/j.issn.1001-5256.2020.04.024
    [14]Chuan LiXue, Chang Jiang, Zhao JinHan, Li LuoHua, Yang XuYao, Yu Di. Association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2020, 36(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2020.06.022
    [15]Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025
    [16]Liu SiFu, Xie ZhengYuan. Association between nonalcoholic fatty liver disease and colorectal tumors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2091-2094. doi: 10.3969/j.issn.1001-5256.2019.09.046
    [17]Zhang XiaXia, Xu HongTuan, Xu YouQing. The natural history and clinical features of nonalcoholic fatty liver disease-related cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 24-26. doi: 10.3969/j.issn.1001-5256.2018.01.004
    [18]Liu JiaQi, Zhou ShaoMing. Research advances in intestinal flora in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2453-2456. doi: 10.3969/j.issn.1001-5256.2017.12.045
    [19]Lu Xu, Han Tao, Tian Yao, Lu BoWei, Zhang Qian. Research progress in roles of gut microbiota and bile acid metabolism in development and progression of NAFLD[J]. Journal of Clinical Hepatology, 2014, 30(11): 1225-1228. doi: 10.3969/j.issn.1001-5256.2014.11.034
    [20]Zhu Peng, Xu Zong, Wang YuMing. World Gastroenterology Organisation global guidelines：nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2014, 30(9): 842-845. doi: 10.3969/j.issn.1001-5256.2014.09.002
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-040102030
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.4 %FULLTEXT: 15.4 %META: 78.3 %META: 78.3 %PDF: 6.3 %PDF: 6.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.3 %其他: 8.3 %其他: 1.0 %其他: 1.0 %Australia: 0.2 %Australia: 0.2 %China: 1.0 %China: 1.0 %Egypt: 0.3 %Egypt: 0.3 %India: 0.8 %India: 0.8 %Iraq: 0.3 %Iraq: 0.3 %Russian Federation: 0.2 %Russian Federation: 0.2 %United Kingdom: 0.1 %United Kingdom: 0.1 %United States: 0.2 %United States: 0.2 %[]: 1.0 %[]: 1.0 %上海: 1.3 %上海: 1.3 %中卫: 1.0 %中卫: 1.0 %临汾: 0.1 %临汾: 0.1 %临沧: 0.1 %临沧: 0.1 %丽水: 0.1 %丽水: 0.1 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %伊犁: 0.1 %伊犁: 0.1 %佛山: 0.1 %佛山: 0.1 %凉山彝族自治州: 0.1 %凉山彝族自治州: 0.1 %北京: 8.1 %北京: 8.1 %北阿坎德: 0.3 %北阿坎德: 0.3 %南京: 0.4 %南京: 0.4 %南充: 0.1 %南充: 0.1 %南宁: 0.4 %南宁: 0.4 %南昌: 0.2 %南昌: 0.2 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %台州: 0.7 %台州: 0.7 %吉林: 1.6 %吉林: 1.6 %呼和浩特: 0.2 %呼和浩特: 0.2 %唐山: 0.8 %唐山: 0.8 %嘉兴: 0.1 %嘉兴: 0.1 %四平: 0.1 %四平: 0.1 %多伦多: 0.1 %多伦多: 0.1 %大连: 0.1 %大连: 0.1 %天津: 1.2 %天津: 1.2 %常德: 0.1 %常德: 0.1 %广州: 0.9 %广州: 0.9 %延边: 0.2 %延边: 0.2 %弗吉尼亚州: 0.1 %弗吉尼亚州: 0.1 %张家口: 1.5 %张家口: 1.5 %徐州: 0.1 %徐州: 0.1 %成都: 0.5 %成都: 0.5 %新乡: 0.1 %新乡: 0.1 %新余: 0.1 %新余: 0.1 %昆明: 1.3 %昆明: 1.3 %晋城: 0.1 %晋城: 0.1 %曼谷: 0.1 %曼谷: 0.1 %朝阳: 0.1 %朝阳: 0.1 %杭州: 0.3 %杭州: 0.3 %松原: 0.1 %松原: 0.1 %武汉: 1.1 %武汉: 1.1 %河池: 0.1 %河池: 0.1 %泰州: 0.1 %泰州: 0.1 %济南: 0.3 %济南: 0.3 %海得拉巴: 0.4 %海得拉巴: 0.4 %淄博: 0.2 %淄博: 0.2 %淮北: 0.1 %淮北: 0.1 %淮安: 0.1 %淮安: 0.1 %深圳: 0.5 %深圳: 0.5 %湖州: 0.1 %湖州: 0.1 %湘潭: 0.1 %湘潭: 0.1 %潍坊: 0.1 %潍坊: 0.1 %珠海: 0.1 %珠海: 0.1 %眉山: 0.1 %眉山: 0.1 %石家庄: 0.2 %石家庄: 0.2 %秦皇岛: 0.1 %秦皇岛: 0.1 %聊城: 0.1 %聊城: 0.1 %芒廷维尤: 37.1 %芒廷维尤: 37.1 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.2 %苏州: 0.2 %莫斯科: 2.4 %莫斯科: 2.4 %莱芜: 0.1 %莱芜: 0.1 %衢州: 0.1 %衢州: 0.1 %襄阳: 0.1 %襄阳: 0.1 %西宁: 15.0 %西宁: 15.0 %贵阳: 0.4 %贵阳: 0.4 %辽阳: 0.1 %辽阳: 0.1 %运城: 1.8 %运城: 1.8 %连云港: 0.1 %连云港: 0.1 %邯郸: 0.1 %邯郸: 0.1 %重庆: 0.3 %重庆: 0.3 %银川: 0.2 %银川: 0.2 %锦州: 0.1 %锦州: 0.1 %长春: 1.4 %长春: 1.4 %长沙: 0.1 %长沙: 0.1 %鞍山: 0.1 %鞍山: 0.1 %香港: 0.1 %香港: 0.1 %鹤壁: 0.1 %鹤壁: 0.1 %黄冈: 0.1 %黄冈: 0.1 %黔南: 0.1 %黔南: 0.1 %其他其他AustraliaChinaEgyptIndiaIraqRussian FederationUnited KingdomUnited States[]上海中卫临汾临沧丽水乌鲁木齐伊犁佛山凉山彝族自治州北京北阿坎德南京南充南宁南昌南阳卡纳塔克台州吉林呼和浩特唐山嘉兴四平多伦多大连天津常德广州延边弗吉尼亚州张家口徐州成都新乡新余昆明晋城曼谷朝阳杭州松原武汉河池泰州济南海得拉巴淄博淮北淮安深圳湖州湘潭潍坊珠海眉山石家庄秦皇岛聊城芒廷维尤芝加哥苏州莫斯科莱芜衢州襄阳西宁贵阳辽阳运城连云港邯郸重庆银川锦州长春长沙鞍山香港鹤壁黄冈黔南

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2431) PDF downloads(431) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2389]YesterdayPV[5285]TodayIP[1960]TodayPV[4323]Online[50]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return